Boston Scientific Corp (NYSE: BSX) on Tuesday, plunged -1.65% from the previous trading day, before settling in for the closing price of $95.72. Within the past 52 weeks, BSX’s price has moved between $85.98 and $109.50.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -17.84%. The company achieved an average annual earnings per share of 20.96%. With a float of $1.48 billion, this company’s outstanding shares have now reached $1.48 billion.
Boston Scientific Corp (BSX) Insider Updates
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Boston Scientific Corp is 0.39%, while institutional ownership is 93.36%. The most recent insider transaction that took place on Dec 01 ’25, was worth 1,758,189. In this transaction EVP& Grp Pres, MedSurg & APAC of this company sold 17,313 shares at a rate of $101.55, taking the stock ownership to the 23,600 shares. Before that another transaction happened on Dec 01 ’25, when Company’s Officer proposed sale 17,313 for $101.55, making the entire transaction worth $1,758,188.
Boston Scientific Corp (BSX) Performance Highlights and Predictions
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported 0.7 earnings per share (EPS) for the period topping the consensus outlook (set at 0.66) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.8 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.96% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.23% during the next five years compared to -17.84% drop over the previous five years of trading.
Boston Scientific Corp (NYSE: BSX) Trading Performance Indicators
Boston Scientific Corp (BSX) is currently performing well based on its current performance indicators. A quick ratio of 0.96 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.21. Likewise, its price to free cash flow for the trailing twelve months is 36.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.87, a number that is poised to hit 0.78 in the next quarter and is forecasted to reach 3.47 in one year’s time.
